Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
Top Cited Papers
- 1 February 2006
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 130 (2), 323-333
- https://doi.org/10.1053/j.gastro.2005.11.030
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Tumor necrosis factor: Biology and therapeutic inhibitorsGastroenterology, 2000
- Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseGastroenterology, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Tumour necrosis factor and Crohn's disease.Gut, 1997
- Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Gut, 1993
- Tumour necrosis factor alpha in stool as a marker of intestinal inflammationThe Lancet, 1992
- Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.Gut, 1991